ArticleSpinal cord2026
Spinal cord injury research and national institutes of health funding: a call to action.
Article in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The unmet burden of secondary SCI complications: lost in translation.Spinal cord · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designCross-sectional study.
objectivesThe magnitude and nature of National Institutes of Health (NIH) funding for spinal cord injury (SCI) research is poorly characterized. This study elucidates the portfolio of NIH grants awarded for SCI research.
settingN/A
methodsData on NIH grants awarded for SCI research were extracted from the NIH RePORTER database (2013-2023). NIH funding was analyzed for twenty-five clinical areas and compound annual growth rates (CAGRs) were calculated over the study period.
resultsFrom 2013-2023, the NIH extramural research budget increased from $28.3 to $45.0 billion (CAGR 4.7%). A total of $986 million was awarded for SCI research, which increased from $93.6 to $97.7 million over the study period (CAGR 0.4%). Among the twenty-five clinical areas, dementia ($21.8 billion, CAGR 18.7%) and diabetes ($20.6 billion, CAGR 21.5%) had the most NIH funding. For SCI research, most NIH funding was awarded by the National Institute of Neurological Disorders and Stroke (67%) via the R01 (57%) grant mechanism. The clinical areas receiving the most NIH funding for SCI research were disease mechanisms (47%), prosthetics (22%), biologic therapies (18%), and pharmacologic therapies (6%). Several principal investigator characteristics were associated with higher NIH funding totals for SCI research including male (P < 0.001), full professor (P < 0.001), and MD, PhD degree (P = 0.044).
conclusionsGrowth in the annual NIH budget for SCI research has not kept pace with growth in the overall NIH extramural research budget. Future strategies are needed to support PIs in obtaining NIH grant funding for SCI research.
Indexed as
Identifiers
41366091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.